-
Novartis Kicks Off $2.5B Share Buyback Program On Strong Pipeline Growth
Tuesday, November 24, 2020 - 7:13am | 329Read More...On Tuesday, Swiss biopharma company Novartis AG (NYSE: NVS) announced a $2.5 billion share buyback program. The management also exhibited a heightened confidence level in its sales projections based on the current pipeline of products under development. What Happened: The...
-
Importance Of Phase III Trials
Monday, July 25, 2016 - 8:50am | 755Read More...After gaining a sufficient understanding of the importance of clinical Phase I and Phase II trials, it's time to move on to the importance of Phase III trials. To recap, a Phase I trial consists of a pharmaceutical company testing a new drug or treatment in a small group of people to evaluate its...
-
Agile Therapeutics Plunges After Company Prices A Stock Offering At $6.35 Per Share
Friday, January 22, 2016 - 1:39pm | 169Read More...Shares of Agile Therapeutics Inc (NASDAQ: AGRX) plunged to a 52-week low of $6.01 on Friday after the company announced a public offering of 5.512 million shares of its common stock at a price of $6.35 per share. Agile Therapeutics' stock closed at $7.06 on Thursday. The company disclosed...
